Recent developments highlight Bausch & Lomb's strong Q3 2026 financial performance, regulatory approvals, and pipeline progress.

• Bausch & Lomb reported third-quarter 2026 revenue of $1.375 billion and raised full-year guidance [N1].
• The company swung to a profit in Q3 2026 and lifted full-year 2026 guidance [N3].
• Bausch & Lomb surpassed Q3 earnings and revenue expectations [N4].
• The company gained European CE Mark approval for its next-generation SeeLyra femtosecond laser and plans to seek approvals globally [N6][N7][N8].
• Bausch & Lomb advanced a dry eye drug to Phase III clinical trials and achieved Phase Ib goals for a pain candidate [N2].

The company has demonstrated operational improvements with a swing to profitability in Q3 2026 and raised full-year guidance, supported by strong revenue performance of $1.375 billion in the quarter. Advancements in pipeline drugs to Phase III and regulatory approvals for innovative devices like the SeeLyra laser indicate progress in product development and market expansion. Cost savings programs and milestone achievements may enhance financial flexibility and shareholder value [N1][N3][N4][N6][N7][N8].

Bausch & Lomb faces risks from potential disruptions due to leadership transitions and uncertainties in strategic direction. The company is subject to ongoing litigation and legal contingencies that could impact cash flows. Capital expenditures and milestone payments represent significant cash outflows. Market volatility and competitive pressures, including potential loss of exclusivity on key products, could adversely affect financial performance. Impairment risks exist if market conditions deteriorate or strategic execution falters [S1][S2].

Bausch & Lomb's moat is supported by its diversified portfolio of branded and generic eye health products, established licensing agreements, and ongoing investment in research and development. Regulatory approvals such as the European CE Mark for its SeeLyra femtosecond laser enhance its competitive positioning. The company's ability to leverage intellectual property, maintain product exclusivity, and execute cost-saving initiatives contributes to operational resilience. However, the company faces risks from patent expirations, competitive pressures, and regulatory challenges [S1][N6][N7][N8].

• Leadership Transition Risks: Recent changes in executive leadership may cause disruption and uncertainty regarding strategic direction, potentially impacting business operations and market perception [S2].
• Legal and Litigation Risks: The company is involved in ongoing litigation and legal proceedings that could affect cash flows and financial condition [S1].
• Financial Obligations: Significant capital expenditures and milestone payments, including a $35 million milestone payment related to licensing agreements, represent cash flow commitments [S1].
• Market and Competitive Risks: Potential loss of product exclusivity, regulatory changes, and competitive pressures could negatively impact revenue and profitability [S1].

• Bausch & Lomb Corp operates primarily in the eye health therapeutic areas, including branded prescription eye medications and pharmaceuticals, generic and branded generic prescription eye medications, OTC vitamin and supplement products, and medical devices such as contact lenses, intraocular lenses (IOLs), and ophthalmic surgical equipment [S1].
• The company recognizes revenue when control of goods or services is transferred to customers, applying a five-step revenue recognition model [S1].
• As of September 30, 2026, Bausch & Lomb reported cash and cash equivalents of $513 million, current assets of $3.055 billion, and current liabilities of $1.96 billion, resulting in a current ratio of 1.56 and a cash ratio of 0.26 [S2].
• Net income for the quarter ended September 30, 2026, was $32 million with basic and diluted EPS of $0.09 [S2].
• The company has ongoing capital expenditures planned for 2026 of approximately $285 million for property, plant, and equipment [S1].
• Bausch & Lomb has accrued a $35 million milestone payment related to a sales-based milestone under a license agreement with Novaliq GmbH, anticipated to be paid in Q1 2026 [S1].
• The company is engaged in cost savings and business transformation initiatives, including potential headcount reductions, real estate cost eliminations, and contribution margin improvements [S1].
• Bausch & Lomb conducts annual goodwill impairment tests and uses discounted cash flow models with Level 3 inputs for valuation; no impairments were recorded through December 31, 2025 [S1].
• The company is involved in ongoing litigation and legal contingencies typical for its industry, which may impact cash flows [S1].
• Recent news reports indicate Bausch & Lomb reported third-quarter 2026 revenue of $1.375 billion and raised full-year guidance [N1].
• The company swung to a profit in Q3 2026 and lifted full-year 2026 guidance [N3].
• Bausch & Lomb surpassed Q3 2026 earnings and revenue expectations [N4].
• The company gained European CE Mark approval for its next-generation SeeLyra femtosecond laser and plans to seek approvals globally [N6,N7,N8].
• Bausch & Lomb advanced a dry eye drug to Phase III clinical trials and achieved Phase Ib goals for a pain candidate [N2].